Imugene Limited (AU:IMU) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Imugene Limited has secured a significant capital boost of up to A$46 million through the issuance of convertible notes and warrants to CVI Investments Inc. This funding is set to support the company’s clinical trials, including programs like azer-cel, onCARlytics, and VAXINIA, extending its cash runway to the end of 2025. The move positions Imugene to anticipate pivotal clinical data in the coming year, offering potential growth opportunities for investors.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Will Shari Redstone’s Relationship With Trump Save Paramount (NASDAQ:PARA) Merger?
- Ford (NYSE:F) Offers Free Cars to Trump Inauguration
- Rest Easy, Intel (NASDAQ:INTC): Broadcom Is Not Coming For You
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
